Related coverage linked through entity extraction aliases.
Mar 18, 2026
Candel Therapeutics secured $100M royalty funding for CAN-2409 and plans a Q4 2026 BLA submission in prostate cancer. Updated NSCLC phase 2a data showed median overall survival of 25.4 months, with a phase 3 trial planned for Q2 2026.
Jul 29, 2026
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
Jun 01, 2026
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
Feb 20, 2026
Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.
